Aptimmune Biologics is a startup based in the United States, most recent round Series B, 1 tracked investor.
Aptimmune Biologics is a startup based in the United States. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
Aptimmune Biologics develops innovative mucosal vaccines targeting economically significant viral diseases in swine, including Porcine Reproductive and Respiratory Syndrome virus (PRRSV), Swine Influenza A virus (IAV-S), and African Swine Fever virus (ASFV).
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.